SCHEMBL2820776

SCHEMBL2820776

COC(=O)[C@@H]1C[C@@H](O)CN1Cc1cccc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP3A4 P08684 2/20 0.45
VHL P40337 1/20 0.44
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
MC3R P41968 1/20 0.42
MC1R Q01726 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CXCR6 O00574 1/20 0.42
PDCD1 Q15116 1/20 0.41
CD274 Q9NZQ7 1/20 0.41
OPRK1 P41145 1/20 0.41
MAPT P10636 1/20 0.41
S1PR1 P21453 1/20 0.41
S1PR5 Q9H228 1/20 0.41
MMP1 P03956 1/20 0.41
ADAM17 P78536 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3639596 0.95 MAOA (0.43) MAOAMAOBKDM4ECYP3A4VHL
SCHEMBL2818883 0.87 CYP3A4 (0.50) MAOAMAOBKDM4ECYP3A4KMT2A
SCHEMBL4249938 0.87 CYP3A4 (0.50) MAOAMAOBKDM4ECYP3A4KMT2A
SCHEMBL1440329 0.87 CYP3A4 (0.50) MAOAMAOBKDM4ECYP3A4KMT2A
SCHEMBL15325590 0.87 CYP3A4 (0.50) MAOAMAOBKDM4ECYP3A4KMT2A
SCHEMBL24938939 0.87 CYP3A4 (0.50) MAOAMAOBKDM4ECYP3A4KMT2A
SCHEMBL5368566 0.87 CYP3A4 (0.50) MAOAMAOBKDM4ECYP3A4KMT2A
SCHEMBL19408855 0.87 CYP3A4 (0.50) MAOAMAOBKDM4ECYP3A4KMT2A
Hydrochloric Acid SCHEMBL6951431 0.86 CYP3A4 (0.49) MAOAMAOBKDM4ECYP3A4KMT2A
SCHEMBL2817870 0.84 ALDH1A1 (0.47) MAOAMAOBKDM4ECYP3A4MC3R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155672-B1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-10-27 EP disclosed
US-7528136-B2 for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS SLC6A3, OPRL1, OPRK1 MAOA 619/4885MAOB 349/4885KDM4E 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.